TAILIEUCHUNG - Hepatitis C virus and non-Hodgkin’s lymphomas: A minireview

B-cell NHL is strongly associated with HCV that was proved in the last 2 decades. The most common HCV infection related B-NHL subtypes include MZL and DLBCL lymphomas. HCV-positive NHL patients usually present with older age at diagnosis, higher LDH, and more extranodal disease. The standard chemo-immunotherapy tolerance is generally good. Antiviral treatment achieves virological and hematological remission in HCV associated indolent lymphoma. More aggressive lymphoma requires combination of antiviral treatment and chemotherapy. New generation of HCV antiviral drugs is safe and is highly efficacious. Regi- mens including DAAs appear promising options as they can reduce the HCV-associated NHL incidence by dramatically lowering the HCV chronic carriers. | Journal of Advanced Research 2017 8 131-137 Cairo University Journal of Advanced Research MINI REVIEW Hepatitis C virus and non-Hodgkin s lymphomas A CrossMark minireview Hussein Khaled a Fouad Abu-Taleb b Rasha Haggagb a Medical Oncology Department National Cancer Institute Cairo University Cairo 11796 Egypt b Medical Oncology Department Faculty of Medicine Zagazig University Zagazig 44519 Egypt GRAPHICAL ABSTRACT ARTICLE INFO Malignant lymphomas and HCV infection have a dual relationship. ABSTRACT Article history Received 31 August 2016 Received in revised form 28 November 2016 Accepted 30 November 2016 Available online 12 December 2016 B-cell NHL is strongly associated with HCV that was proved in the last 2 decades. The most common HCV infection related B-NHL subtypes include MZL and DLBCL lymphomas. HCV-positive NHL patients usually present with older age at diagnosis higher LDH and more extranodal disease. The standard chemo-immunotherapy tolerance is generally good. Antiviral treatment achieves virological and hematological remission in HCV associated indolent lymphoma. More aggressive lymphoma requires combination of antiviral treatment and chemotherapy. New generation of HCV antiviral drugs is safe and is highly efficacious. Regi- Corresponding author. E-mail address khussein528@ H. Khaled . Peer review under responsibility of Cairo University. Production and hosting by Elsevier http 2090-1232 2016 Production and hosting by Elsevier . on behalf of Cairo University. This is an open access article under the CC BY-NC-ND license http licenses by-nc-nd . 132 H. Khaled et al. Keywords Hepatitis C virus Non-Hodgkin lymphoma Pathogenesis Antiviral treatment mens including DAAs appear promising options as they can reduce the HCV-associated NHL incidence by dramatically lowering the HCV chronic carriers. 2016 Production and hosting by Elsevier . on behalf of Cairo University. This is an open

• Y khoa - Dược
• Hepatitis C virus
• Non Hodgkin lymphoma
• Antiviral treatment
• Hepatitis C virus
• Non Hodgkin’s lymphomas
• BMC Pediatrics
• Hepatitis B virus
• Hepatitis B surface antibody
• HBV antigen
• BMC Cancer
• Hepatocellular carcinoma
• Hepatitis D virus
• Direct acting antivirals
• Prevalence of hepatitis C Virus
• Infection in a patients attending
• Liver failure
• Sequence heterogeneity in the core
• NS5A region of hepatitis C Virus
• IL 28B polymorphisms in predicting treatment response
• Chronic HCV genotype 4 infected
• Pilot study of occult hepatitis C virus
• Occult hepatitis C virus
• Egyptian blood donors
• HCV RNA from plasma
• Blood donors according to presence of HCV RNA
• Phylogenetic tree
• NS5B based genotyping
• Patients from Damietta governorate
• 50 UTR hepatitis C virus
• Cancer risk
• Chronic hepatitis infection
• Confidence intervals
• Cardiovascular risk
• Hepatitis C virus and cardiovascular
• HCV infection
• Increase cardiovascular risk
• BMC Musculoskeletal Disorders
• Human immunodeficiency virus
• Chronic HCV monoinfection
• Ascertain joint pain
• Hepatitis C virus genotype 4
• Chronic hepatitis
• Promoter methylation
• Disease progression
• Solid tumors
• HBV screening
• Hepatitis C
• Hepatitis C virus infection
• Neurological and psychiatric disorders
• Magnetic resonance spectroscopy
• HIV infection
• Direct acting antiviral agents
• Treating chronic hepatitis C infection
• Occult hepatitis C infection
• Clinical relevance
• Lymphoproliferative disorders
• Interferon lambda 3
• Hepatic steatosis
• Chronic hepatitis cirrhosis
• Transfusion transmitted infections
• Tertiary care hospital
• Report medicine
• traditional medicine
• scientific reports
• immune system
• Antimicrobial
• biosynthesis
• Current level of evidence
• Causal association
• Type 2 diabetes
• Insulin resistance
• Extrahepatic manifestations vasculitis
• Direct acting anti HCV drugs
• Vasculitis to serum cryoglobulins
• Different mechanisms
• New era for management
• Chronic hepatitis C virus
• Antiviral agents
• Direct antiviral agents
• Protease inhibitors
• Polymerase inhibitors
• Occult HCV
• Peripheral blood mononuclear cells
• Direct acting antiviral drugs
• Sofosbuvir and daclatasvir
• miR 122
• miR 134
• miR 424
• miR 629
• Receiver operating characteristic
• Summary thesis’ doctor of medicine
• Research of hepatitis C virus genotypes
• Hepatocellular carcinoma patients
• Evaluating relationship between HCV genotypes
• Characteristics laboratory features
• Blood transfusion
• Seroprevalence of Hepatitis B
• C virus
• Blood donors